PETNET Solutions Australia/ Cyclotek

ETNET and Cyclotek manufacture radiopharmaceuticals used in PET (positron emission tomography) scanning. PET is mainly used in the diagnosis and treatment assessment of oncology patients. Both companies produce a compound known as FDG (Fludeoxyglucose [18F]).

The use of PET/CT (a combination of PET and CT) is increasing as awareness of its value grows. Unlike conventional imaging (CT, MRI, US) which relies on physical size to assess a tumour, PET is sensitive to cellular activity (metabolism). This type of information about a tumour is especially useful when assessing treatment response. Studies have shown that in some cases PET results in changes to treatment plans in 52% of patients.

The industry is seeking to raise awareness of how this valuable clinical tool can benefit patients.